In the grand theater of global finance, where algorithms dance to the tune of geopolitical pronouncements, few maestros command the stage quite like Donald J. Trump. This past week, markets once again found themselves on a rollercoaster, lurching from the precipice of a full-blown trade war to the gentle slopes of pharmaceutical price cuts, all at the whim of a single, influential voice. Investors, it seems, have learned to strap in, as the former (and potentially future) President continues his unique brand of economic diplomacy, often characterized by a policy pivot so swift it could give a seasoned trader whiplash. The latest episodes? A dramatic tariff tango with China and a surprising intervention into the intimate world of IVF, alongside a broadside against weight-loss drug prices.<\/p>\n
Just last Friday, October 10, 2025, the financial world collectively braced for impact. President Trump, never one for subtlety, announced his intention to slap an additional 100% tariff on Chinese imports, effective November 1. This aggressive move was framed as a direct response to China’s tightening controls on rare-earth mineral exports, a critical component for everything from smartphones to fighter jets. The market’s reaction was immediate and visceral. The S&P 500<\/a> plummeted 2.7%, the Dow Jones Industrial Average<\/a> shed a hefty 1.9% (or nearly 880 points), and the tech-heavy Nasdaq Composite<\/a> sank a dramatic 3.6%, experiencing an intraday fall of up to 5%. It was, by many accounts, the worst single-day sell-off for US equities since April.<\/p>\n Analysts, still reeling from the sudden escalation, pointed to the profound influence of geopolitical rhetoric on investor sentiment. MUFG Research noted that “risk assets including the S&P500 fell sharply on the back of these developments,” highlighting the accompanying weakness in the US Dollar and Chinese Yuan, alongside a rally in safe-haven assets like gold<\/a>. The consensus was clear: a renewed trade war, with tariffs stacking up to a potential 155% on some goods, represented a “practical embargo on most imports” and a significant threat to global supply chains.<\/p>\n Then, as if on cue, the narrative shifted. On Sunday, October 12, President Trump took to his preferred social media platform, Truth Social, to deliver a message of calm: “Don’t worry about China, it will all be fine! Highly respected President Xi just had a bad moment. He doesn’t want Depression for his country, and neither do I. The U.S.A. wants to help China, not hurt it!!!”. This abrupt change in tone, coming just days after accusing China of “a moral disgrace,” sent markets soaring on Monday, October 13. The S&P 500<\/a> rebounded by 1.1% to 1.6%, the Dow Jones Industrial Average<\/a> climbed 1.3% to 1.3%, and the Nasdaq Composite<\/a> jumped an impressive 1.7% to 2.2%. This “down-and-up” movement, as one report put it, echoed similar “manic swings” observed earlier in the year.<\/p>\n The latest twist came on Friday, October 17, when Trump, in an interview with Fox Business Network, declared that his proposed 100% tariffs on Chinese goods were “not sustainable” but insisted he was “forced” to impose them. He also confirmed an upcoming meeting with Chinese President Xi Jinping in South Korea, a meeting he had previously cast doubt upon. This further softening of rhetoric saw major US stock indexes paring earlier declines and trading modestly higher, with the Dow<\/a> up 0.2%, the S&P 500<\/a> up 0.1%, and the Nasdaq<\/a> also gaining 0.1% in recent trading. It seems the market, much like a seasoned poker player, is learning to read the tells, even if those tells are delivered via social media and then contradicted on cable news.<\/p>\n Beyond the high-stakes trade theatrics, President Trump also turned his attention to the more intimate, yet equally financially burdensome, realm of fertility treatments. On Thursday, October 16, he announced a deal with Germany’s Merck KGaA (specifically its U.S. subsidiary, EMD Serono) to drastically reduce the cost of several key IVF fertility medications. Under the agreement, eligible patients using all three of Merck KGaA’s IVF therapies\u2014Gonal-f, Ovidrel, and Cetrotide\u2014could see an 84% discount off list prices. The White House even highlighted that Gonal-f was “700% more expensive in the United States than in the rest of the world”.<\/p>\n The quid pro quo for this pharmaceutical benevolence? Relief from threatened tariffs on pharmaceutical imports and a commitment from Merck KGaA to boost its manufacturing and research footprint within the United States. Furthermore, the deal promises an accelerated FDA review for Merck KGaA’s new fertility drug, Pergoveris, cutting the evaluation period from up to a year down to a mere one to two months. It’s a curious arrangement, where the threat of tariffs acts as both stick and carrot, coercing price reductions while simultaneously incentivizing domestic production. The fertility benefits provider Progyny<\/a> (PGNY<\/a>) saw its shares swing wildly, initially gaining ~5% on Thursday as news of the initiative broke, only to fall ~10% on Friday as analysts expressed concerns that lower cash-pay prices could erode Progyny’s revenue stream.<\/p>\n Not content with merely addressing fertility, President Trump also waded into the booming market for weight-loss drugs. On the same day as the IVF announcement, Thursday, October 16, he promised to drive down the prices of popular GLP-1 agonists like Novo Nordisk’s Ozempic and Eli Lilly’s Zepbound\/Mounjaro. Suggesting that monthly costs could drop from their current $1,000-$1,300 range to as low as $150, Trump’s remarks sent shivers down the spines of pharmaceutical investors.<\/p>\n The market reacted swiftly on Friday, October 17. Shares of Novo Nordisk<\/a> (NVO<\/a>) tumbled by approximately 4% to 6% in early and pre-market trading<\/a>. Similarly, Eli Lilly<\/a> (LLY<\/a>) saw its stock drop by 3% to 4%. Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services (CMS<\/a>), later clarified that negotiations for these specific GLP-1 drugs were still ongoing but would continue until the President was “satisfied with the outcome”. Despite the immediate sell-off, some analysts, including those from JPMorgan and BMO Capital Markets, suggested the negative reaction might be “overdone,” citing the potential for increased sales volume at lower prices and the fact that some insured patients already pay significantly less. UBS analysts, it seems, had already factored in potential price cuts for Novo Nordisk.<\/p>\nThe IVF Intervention: A Pharmaceutical Puzzler and the Price of Life<\/h2>\n
Weight-Loss Wonders: Ozempic and the Art of the Discount<\/h2>\n
Truth Social’s Market Musings: The Digital Pulpit<\/h2>\n